| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Deductibles and Coinsurance | 37 | 2023 | 315 | 6.150 |
Why?
|
| Drug Costs | 33 | 2021 | 1193 | 2.560 |
Why?
|
| Health Maintenance Organizations | 25 | 2013 | 656 | 2.500 |
Why?
|
| Drug Utilization | 35 | 2020 | 1187 | 2.120 |
Why?
|
| Cost Sharing | 16 | 2024 | 409 | 2.100 |
Why?
|
| Diabetes Mellitus | 31 | 2024 | 5891 | 2.010 |
Why?
|
| Drug Prescriptions | 37 | 2021 | 1662 | 1.940 |
Why?
|
| Patient Compliance | 17 | 2017 | 2692 | 1.900 |
Why?
|
| Inappropriate Prescribing | 4 | 2021 | 211 | 1.840 |
Why?
|
| Insurance, Health | 31 | 2022 | 2521 | 1.830 |
Why?
|
| Health Expenditures | 28 | 2024 | 2387 | 1.820 |
Why?
|
| Drugs, Essential | 9 | 2020 | 71 | 1.690 |
Why?
|
| Insurance Coverage | 23 | 2020 | 1944 | 1.500 |
Why?
|
| Financing, Personal | 13 | 2020 | 310 | 1.490 |
Why?
|
| Hypoglycemic Agents | 15 | 2024 | 3110 | 1.340 |
Why?
|
| Health Policy | 26 | 2020 | 2698 | 1.280 |
Why?
|
| Medicare Part D | 14 | 2021 | 355 | 1.270 |
Why?
|
| Health Services Accessibility | 23 | 2022 | 5508 | 1.260 |
Why?
|
| Health Benefit Plans, Employee | 4 | 2017 | 331 | 1.220 |
Why?
|
| Community Health Services | 5 | 2020 | 657 | 1.150 |
Why?
|
| Diabetes Complications | 6 | 2024 | 1316 | 1.140 |
Why?
|
| Respiratory Tract Infections | 10 | 2021 | 1008 | 1.130 |
Why?
|
| Insurance, Pharmaceutical Services | 17 | 2011 | 347 | 1.080 |
Why?
|
| Developing Countries | 15 | 2022 | 2911 | 1.070 |
Why?
|
| Medicaid | 34 | 2021 | 2833 | 1.010 |
Why?
|
| Poverty | 17 | 2022 | 2714 | 1.000 |
Why?
|
| Workload | 2 | 2021 | 851 | 0.950 |
Why?
|
| National Health Programs | 6 | 2019 | 443 | 0.950 |
Why?
|
| Drug Therapy | 11 | 2014 | 504 | 0.920 |
Why?
|
| Benzodiazepines | 10 | 2015 | 1136 | 0.850 |
Why?
|
| Medication Adherence | 14 | 2021 | 2192 | 0.840 |
Why?
|
| Antihypertensive Agents | 10 | 2019 | 2033 | 0.840 |
Why?
|
| Pharmaceutical Preparations | 6 | 2013 | 1084 | 0.830 |
Why?
|
| Pharmacies | 6 | 2019 | 171 | 0.810 |
Why?
|
| China | 12 | 2023 | 2385 | 0.800 |
Why?
|
| Gastric Bypass | 8 | 2024 | 820 | 0.790 |
Why?
|
| Carbapenems | 1 | 2023 | 125 | 0.790 |
Why?
|
| Medical Savings Accounts | 3 | 2022 | 34 | 0.790 |
Why?
|
| Healthcare Disparities | 8 | 2018 | 3413 | 0.780 |
Why?
|
| Blood Glucose Self-Monitoring | 5 | 2019 | 475 | 0.740 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2024 | 253 | 0.700 |
Why?
|
| Bronchitis | 1 | 2021 | 193 | 0.700 |
Why?
|
| Medicare | 24 | 2022 | 6823 | 0.690 |
Why?
|
| Contraception | 2 | 2021 | 361 | 0.690 |
Why?
|
| Patient Acceptance of Health Care | 12 | 2020 | 3230 | 0.670 |
Why?
|
| Health Personnel | 5 | 2022 | 3390 | 0.660 |
Why?
|
| Emergency Service, Hospital | 15 | 2021 | 7875 | 0.660 |
Why?
|
| Speech Recognition Software | 2 | 2010 | 74 | 0.660 |
Why?
|
| Drug Utilization Review | 10 | 2015 | 248 | 0.650 |
Why?
|
| Humans | 293 | 2024 | 765968 | 0.650 |
Why?
|
| Health Care Costs | 15 | 2024 | 3242 | 0.640 |
Why?
|
| Middle Aged | 132 | 2024 | 223009 | 0.640 |
Why?
|
| Treatment Refusal | 7 | 2013 | 433 | 0.630 |
Why?
|
| Ambulatory Care | 5 | 2017 | 2778 | 0.620 |
Why?
|
| Adult | 123 | 2023 | 223044 | 0.600 |
Why?
|
| Telephone | 4 | 2014 | 627 | 0.600 |
Why?
|
| Delayed Diagnosis | 2 | 2019 | 452 | 0.590 |
Why?
|
| Frail Elderly | 2 | 2020 | 785 | 0.590 |
Why?
|
| Obesity, Morbid | 7 | 2024 | 1292 | 0.590 |
Why?
|
| Diabetes Mellitus, Type 2 | 14 | 2024 | 12240 | 0.580 |
Why?
|
| Female | 169 | 2024 | 396112 | 0.580 |
Why?
|
| Bipolar Disorder | 10 | 2022 | 5138 | 0.570 |
Why?
|
| Mammography | 5 | 2022 | 2423 | 0.570 |
Why?
|
| Family Characteristics | 6 | 2016 | 1001 | 0.570 |
Why?
|
| Appointments and Schedules | 4 | 2020 | 444 | 0.570 |
Why?
|
| Early Detection of Cancer | 6 | 2020 | 3236 | 0.550 |
Why?
|
| Guideline Adherence | 7 | 2014 | 2243 | 0.540 |
Why?
|
| Reimbursement Mechanisms | 11 | 2021 | 672 | 0.530 |
Why?
|
| Anti-Bacterial Agents | 11 | 2023 | 7478 | 0.530 |
Why?
|
| United States | 90 | 2024 | 72903 | 0.520 |
Why?
|
| Program Evaluation | 8 | 2020 | 2499 | 0.510 |
Why?
|
| Patient Readmission | 7 | 2020 | 3286 | 0.500 |
Why?
|
| Hypolipidemic Agents | 3 | 2017 | 608 | 0.500 |
Why?
|
| Health Care Reform | 6 | 2016 | 1259 | 0.500 |
Why?
|
| Diarrhea | 4 | 2014 | 1316 | 0.500 |
Why?
|
| Health Services Research | 11 | 2015 | 1808 | 0.500 |
Why?
|
| Nonprescription Drugs | 1 | 2016 | 119 | 0.500 |
Why?
|
| Breast Neoplasms | 15 | 2022 | 21056 | 0.490 |
Why?
|
| Chronic Disease | 14 | 2021 | 9347 | 0.490 |
Why?
|
| Male | 142 | 2024 | 363698 | 0.490 |
Why?
|
| Fees, Pharmaceutical | 6 | 2011 | 66 | 0.490 |
Why?
|
| Medical Indigency | 4 | 2011 | 63 | 0.490 |
Why?
|
| Mass Screening | 6 | 2017 | 5446 | 0.470 |
Why?
|
| Length of Stay | 8 | 2017 | 6485 | 0.470 |
Why?
|
| Antidepressive Agents | 9 | 2017 | 2897 | 0.460 |
Why?
|
| Quality Assurance, Health Care | 6 | 2018 | 2172 | 0.460 |
Why?
|
| Aged | 92 | 2024 | 171117 | 0.450 |
Why?
|
| Anti-Anxiety Agents | 3 | 2007 | 402 | 0.450 |
Why?
|
| Malaria | 3 | 2014 | 1246 | 0.450 |
Why?
|
| Continuity of Patient Care | 3 | 2017 | 1078 | 0.440 |
Why?
|
| Vulnerable Populations | 2 | 2019 | 718 | 0.440 |
Why?
|
| Longitudinal Studies | 23 | 2021 | 14751 | 0.430 |
Why?
|
| Patient Protection and Affordable Care Act | 8 | 2022 | 1188 | 0.430 |
Why?
|
| Medication Therapy Management | 1 | 2014 | 131 | 0.430 |
Why?
|
| Cluster Analysis | 5 | 2014 | 2721 | 0.420 |
Why?
|
| Preventive Medicine | 1 | 2015 | 246 | 0.420 |
Why?
|
| Patient Admission | 4 | 2017 | 1365 | 0.420 |
Why?
|
| Adolescent | 56 | 2021 | 88835 | 0.420 |
Why?
|
| Private Practice | 2 | 2004 | 154 | 0.420 |
Why?
|
| Gastrectomy | 7 | 2024 | 694 | 0.410 |
Why?
|
| Socioeconomic Factors | 22 | 2017 | 7838 | 0.410 |
Why?
|
| Young Adult | 40 | 2021 | 59889 | 0.410 |
Why?
|
| Hospitalization | 14 | 2021 | 10808 | 0.410 |
Why?
|
| Regression Analysis | 10 | 2016 | 6322 | 0.410 |
Why?
|
| Postnatal Care | 5 | 2016 | 275 | 0.400 |
Why?
|
| Gastrointestinal Diseases | 4 | 2011 | 1203 | 0.390 |
Why?
|
| Sexual Behavior | 2 | 2019 | 2193 | 0.390 |
Why?
|
| Insurance Claim Review | 13 | 2021 | 746 | 0.380 |
Why?
|
| Health Care Surveys | 12 | 2013 | 2424 | 0.380 |
Why?
|
| Quality of Health Care | 15 | 2018 | 4300 | 0.380 |
Why?
|
| Heart Diseases | 2 | 2024 | 2821 | 0.380 |
Why?
|
| Quality Control | 1 | 2014 | 837 | 0.380 |
Why?
|
| Suicide, Attempted | 1 | 2020 | 1409 | 0.370 |
Why?
|
| Cost of Illness | 5 | 2019 | 1950 | 0.370 |
Why?
|
| Acute Disease | 5 | 2016 | 7232 | 0.370 |
Why?
|
| Cross-Sectional Studies | 25 | 2021 | 26318 | 0.370 |
Why?
|
| Massachusetts | 22 | 2016 | 8875 | 0.360 |
Why?
|
| Public Sector | 3 | 2011 | 264 | 0.360 |
Why?
|
| Prescription Fees | 6 | 2014 | 153 | 0.350 |
Why?
|
| Cohort Studies | 34 | 2024 | 41649 | 0.350 |
Why?
|
| Income | 7 | 2021 | 1874 | 0.340 |
Why?
|
| Primary Health Care | 9 | 2023 | 4736 | 0.330 |
Why?
|
| Social Class | 4 | 2015 | 2007 | 0.330 |
Why?
|
| Commerce | 5 | 2020 | 611 | 0.330 |
Why?
|
| Legislation, Drug | 4 | 2007 | 217 | 0.330 |
Why?
|
| Colorectal Neoplasms | 4 | 2016 | 6942 | 0.330 |
Why?
|
| Evaluation Studies as Topic | 1 | 2011 | 1600 | 0.320 |
Why?
|
| Physicians | 6 | 2021 | 4588 | 0.320 |
Why?
|
| Data Collection | 9 | 2010 | 3318 | 0.320 |
Why?
|
| Health Surveys | 7 | 2013 | 4056 | 0.320 |
Why?
|
| Philippines | 4 | 2020 | 95 | 0.320 |
Why?
|
| Confidence Intervals | 5 | 2013 | 2910 | 0.310 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 1899 | 0.310 |
Why?
|
| Retrospective Studies | 42 | 2024 | 81514 | 0.310 |
Why?
|
| Community-Institutional Relations | 1 | 2010 | 209 | 0.300 |
Why?
|
| Drugs, Generic | 4 | 2019 | 456 | 0.300 |
Why?
|
| Policy Making | 3 | 2011 | 546 | 0.290 |
Why?
|
| Insurance, Hospitalization | 1 | 2007 | 30 | 0.280 |
Why?
|
| Midwifery | 1 | 2009 | 132 | 0.280 |
Why?
|
| Antipsychotic Agents | 8 | 2022 | 3076 | 0.280 |
Why?
|
| Brazil | 6 | 2020 | 1248 | 0.270 |
Why?
|
| Insurance Benefits | 3 | 2015 | 186 | 0.270 |
Why?
|
| Drug Industry | 8 | 2018 | 791 | 0.270 |
Why?
|
| Anti-Retroviral Agents | 3 | 2013 | 1787 | 0.270 |
Why?
|
| Patient Discharge | 6 | 2020 | 3461 | 0.270 |
Why?
|
| Hypertension | 9 | 2020 | 8626 | 0.260 |
Why?
|
| Interviews as Topic | 10 | 2018 | 2739 | 0.260 |
Why?
|
| Insulin | 5 | 2024 | 6599 | 0.260 |
Why?
|
| Costs and Cost Analysis | 7 | 2021 | 1668 | 0.260 |
Why?
|
| Aftercare | 2 | 2020 | 911 | 0.260 |
Why?
|
| Respiratory Tract Diseases | 1 | 2011 | 744 | 0.260 |
Why?
|
| Health Services Needs and Demand | 2 | 2013 | 1406 | 0.250 |
Why?
|
| Delivery of Health Care | 10 | 2019 | 5370 | 0.250 |
Why?
|
| Mental Health | 1 | 2020 | 3278 | 0.250 |
Why?
|
| Models, Statistical | 2 | 2011 | 5089 | 0.250 |
Why?
|
| Multivariate Analysis | 12 | 2015 | 12056 | 0.250 |
Why?
|
| Antineoplastic Agents | 7 | 2021 | 13648 | 0.250 |
Why?
|
| Electronic Health Records | 3 | 2020 | 4873 | 0.250 |
Why?
|
| Economic Recession | 3 | 2014 | 79 | 0.240 |
Why?
|
| Nicaragua | 2 | 2015 | 29 | 0.240 |
Why?
|
| Honduras | 2 | 2015 | 39 | 0.240 |
Why?
|
| Prescriptions | 2 | 2008 | 388 | 0.240 |
Why?
|
| Prenatal Care | 2 | 2011 | 1160 | 0.240 |
Why?
|
| Residence Characteristics | 5 | 2018 | 2116 | 0.240 |
Why?
|
| Managed Care Programs | 3 | 2008 | 934 | 0.240 |
Why?
|
| Logistic Models | 14 | 2020 | 13266 | 0.230 |
Why?
|
| Cost Control | 11 | 2014 | 624 | 0.230 |
Why?
|
| Severity of Illness Index | 4 | 2011 | 15880 | 0.230 |
Why?
|
| Uganda | 6 | 2014 | 1353 | 0.230 |
Why?
|
| New Jersey | 9 | 2007 | 296 | 0.230 |
Why?
|
| Guatemala | 2 | 2015 | 161 | 0.230 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2014 | 2047 | 0.230 |
Why?
|
| Occult Blood | 3 | 2016 | 198 | 0.220 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 2 | 2003 | 41 | 0.220 |
Why?
|
| Age Factors | 12 | 2019 | 18380 | 0.220 |
Why?
|
| Time Factors | 17 | 2019 | 40065 | 0.220 |
Why?
|
| Hospital Costs | 2 | 2015 | 956 | 0.220 |
Why?
|
| Jaundice, Neonatal | 1 | 2004 | 70 | 0.220 |
Why?
|
| Africa, Eastern | 4 | 2013 | 76 | 0.210 |
Why?
|
| Eligibility Determination | 4 | 2020 | 423 | 0.210 |
Why?
|
| Hospitals, District | 1 | 2004 | 115 | 0.210 |
Why?
|
| Penicillins | 2 | 2023 | 404 | 0.210 |
Why?
|
| Analgesics, Opioid | 6 | 2016 | 3835 | 0.210 |
Why?
|
| Fee-for-Service Plans | 4 | 2017 | 716 | 0.210 |
Why?
|
| Reye Syndrome | 2 | 2000 | 28 | 0.210 |
Why?
|
| Child, Preschool | 26 | 2021 | 42500 | 0.210 |
Why?
|
| Survivors | 3 | 2022 | 2372 | 0.200 |
Why?
|
| Aged, 80 and over | 25 | 2021 | 59489 | 0.200 |
Why?
|
| Research Design | 7 | 2014 | 6209 | 0.200 |
Why?
|
| State Health Plans | 7 | 2013 | 220 | 0.200 |
Why?
|
| Drug Approval | 3 | 2021 | 818 | 0.200 |
Why?
|
| Child | 33 | 2021 | 80564 | 0.200 |
Why?
|
| Tanzania | 2 | 2017 | 1407 | 0.200 |
Why?
|
| Anti-HIV Agents | 4 | 2014 | 4559 | 0.200 |
Why?
|
| Community Pharmacy Services | 2 | 2019 | 51 | 0.200 |
Why?
|
| Thiazolidinediones | 2 | 2015 | 459 | 0.200 |
Why?
|
| Gatekeeping | 4 | 2010 | 49 | 0.190 |
Why?
|
| Health Status Disparities | 2 | 2016 | 1880 | 0.190 |
Why?
|
| Infant | 22 | 2020 | 36386 | 0.190 |
Why?
|
| Private Sector | 2 | 2016 | 396 | 0.190 |
Why?
|
| Pharmaceutical Services | 3 | 2008 | 145 | 0.190 |
Why?
|
| Helicobacter pylori | 2 | 2005 | 380 | 0.190 |
Why?
|
| Oxycodone | 3 | 2015 | 143 | 0.190 |
Why?
|
| Delivery, Obstetric | 1 | 2009 | 946 | 0.190 |
Why?
|
| Helicobacter Infections | 2 | 2005 | 390 | 0.190 |
Why?
|
| World Health Organization | 6 | 2016 | 1328 | 0.190 |
Why?
|
| Psychotropic Drugs | 5 | 2015 | 879 | 0.190 |
Why?
|
| Education, Medical, Continuing | 4 | 2004 | 830 | 0.180 |
Why?
|
| Disabled Persons | 6 | 2021 | 1208 | 0.180 |
Why?
|
| HIV Infections | 7 | 2014 | 17533 | 0.180 |
Why?
|
| Breast Feeding | 3 | 2004 | 1364 | 0.180 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2021 | 138 | 0.180 |
Why?
|
| Kenya | 7 | 2014 | 758 | 0.170 |
Why?
|
| New York | 5 | 2007 | 880 | 0.170 |
Why?
|
| New England | 4 | 2018 | 1059 | 0.170 |
Why?
|
| Product Surveillance, Postmarketing | 3 | 1994 | 464 | 0.170 |
Why?
|
| Case Management | 1 | 2021 | 277 | 0.170 |
Why?
|
| Hip Fractures | 2 | 2007 | 997 | 0.160 |
Why?
|
| Sex Factors | 9 | 2014 | 10603 | 0.160 |
Why?
|
| Sampling Studies | 4 | 2010 | 607 | 0.160 |
Why?
|
| Depressive Disorder | 3 | 2007 | 3714 | 0.160 |
Why?
|
| Hernia, Hiatal | 1 | 2020 | 90 | 0.160 |
Why?
|
| Asthma | 4 | 2023 | 6270 | 0.160 |
Why?
|
| Patient Education as Topic | 2 | 2008 | 2334 | 0.160 |
Why?
|
| Neoplasms | 7 | 2021 | 22340 | 0.160 |
Why?
|
| Negotiating | 1 | 2021 | 152 | 0.160 |
Why?
|
| Models, Theoretical | 2 | 2010 | 3564 | 0.160 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2020 | 390 | 0.160 |
Why?
|
| Choice Behavior | 2 | 2017 | 844 | 0.160 |
Why?
|
| Thailand | 5 | 2020 | 287 | 0.160 |
Why?
|
| Pharmacy | 1 | 2020 | 92 | 0.160 |
Why?
|
| Health Promotion | 4 | 2018 | 2208 | 0.150 |
Why?
|
| Polypharmacy | 2 | 2014 | 306 | 0.150 |
Why?
|
| Attitude of Health Personnel | 5 | 2018 | 3925 | 0.150 |
Why?
|
| Anti-Ulcer Agents | 3 | 2010 | 112 | 0.150 |
Why?
|
| Risk Factors | 18 | 2021 | 74840 | 0.150 |
Why?
|
| Blindness | 6 | 1996 | 586 | 0.140 |
Why?
|
| Family Health | 3 | 2012 | 1253 | 0.140 |
Why?
|
| Health Services for the Aged | 1 | 2020 | 265 | 0.140 |
Why?
|
| Reimbursement, Incentive | 2 | 2014 | 541 | 0.140 |
Why?
|
| Infant, Newborn | 14 | 2020 | 26346 | 0.140 |
Why?
|
| Contraceptive Agents | 1 | 2019 | 147 | 0.140 |
Why?
|
| Antidiarrheals | 2 | 1996 | 46 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2007 | 4058 | 0.140 |
Why?
|
| Drug and Narcotic Control | 3 | 2014 | 144 | 0.140 |
Why?
|
| Malaysia | 3 | 2023 | 107 | 0.140 |
Why?
|
| Medical Audit | 3 | 2009 | 452 | 0.140 |
Why?
|
| Colonoscopy | 3 | 2016 | 1406 | 0.140 |
Why?
|
| Health Services | 4 | 2014 | 756 | 0.140 |
Why?
|
| Condoms | 1 | 2019 | 336 | 0.130 |
Why?
|
| Anticonvulsants | 4 | 2011 | 1921 | 0.130 |
Why?
|
| Self Care | 4 | 2015 | 800 | 0.130 |
Why?
|
| Biopsy | 2 | 2019 | 6763 | 0.130 |
Why?
|
| Xerophthalmia | 1 | 1996 | 12 | 0.130 |
Why?
|
| Education, Pharmacy | 1 | 1996 | 38 | 0.130 |
Why?
|
| Linear Models | 4 | 2017 | 5876 | 0.130 |
Why?
|
| Marketing | 2 | 2009 | 225 | 0.130 |
Why?
|
| Pain | 3 | 2015 | 5077 | 0.130 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2021 | 572 | 0.130 |
Why?
|
| Financing, Government | 1 | 2020 | 473 | 0.130 |
Why?
|
| Medical Assistance | 1 | 2016 | 109 | 0.130 |
Why?
|
| Nursing Homes | 3 | 2020 | 1084 | 0.130 |
Why?
|
| Weight Loss | 3 | 2024 | 2710 | 0.130 |
Why?
|
| Taiwan | 2 | 2015 | 521 | 0.130 |
Why?
|
| Warfarin | 4 | 2008 | 1494 | 0.130 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2016 | 123 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 4 | 2014 | 2686 | 0.120 |
Why?
|
| Family Practice | 3 | 2013 | 508 | 0.120 |
Why?
|
| New Hampshire | 7 | 2010 | 174 | 0.120 |
Why?
|
| Safety-Based Drug Withdrawals | 1 | 2015 | 36 | 0.120 |
Why?
|
| Government Regulation | 1 | 2019 | 525 | 0.120 |
Why?
|
| Home Infusion Therapy | 1 | 1995 | 18 | 0.120 |
Why?
|
| Health Education | 5 | 2008 | 1060 | 0.120 |
Why?
|
| New York City | 1 | 2017 | 733 | 0.120 |
Why?
|
| Medically Uninsured | 1 | 2020 | 838 | 0.120 |
Why?
|
| Schizophrenia | 6 | 2015 | 6972 | 0.120 |
Why?
|
| Diagnostic Imaging | 2 | 2019 | 3529 | 0.120 |
Why?
|
| Jordan | 1 | 2014 | 73 | 0.120 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2017 | 429 | 0.120 |
Why?
|
| Cooperative Behavior | 1 | 2001 | 1509 | 0.110 |
Why?
|
| Administration, Oral | 3 | 2021 | 4015 | 0.110 |
Why?
|
| Conservation of Natural Resources | 1 | 2016 | 209 | 0.110 |
Why?
|
| Mental Disorders | 3 | 2004 | 6853 | 0.110 |
Why?
|
| Africa | 3 | 2011 | 725 | 0.110 |
Why?
|
| Follow-Up Studies | 11 | 2019 | 39193 | 0.110 |
Why?
|
| Tolmetin | 1 | 1993 | 24 | 0.110 |
Why?
|
| BRCA1 Protein | 1 | 2020 | 1153 | 0.110 |
Why?
|
| Odds Ratio | 5 | 2021 | 9649 | 0.110 |
Why?
|
| Prescription Drugs | 2 | 2013 | 634 | 0.110 |
Why?
|
| Patient Transfer | 2 | 2017 | 790 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 7425 | 0.110 |
Why?
|
| Gastroplasty | 1 | 2015 | 153 | 0.110 |
Why?
|
| Diabetic Angiopathies | 1 | 2018 | 805 | 0.110 |
Why?
|
| Organizational Policy | 3 | 2011 | 434 | 0.110 |
Why?
|
| Community Health Planning | 1 | 2014 | 164 | 0.110 |
Why?
|
| Dyspepsia | 2 | 2005 | 115 | 0.110 |
Why?
|
| Ghana | 1 | 2014 | 333 | 0.110 |
Why?
|
| Infection Control | 1 | 2000 | 983 | 0.110 |
Why?
|
| Blood Glucose | 2 | 2019 | 6424 | 0.100 |
Why?
|
| Competitive Medical Plans | 1 | 2013 | 26 | 0.100 |
Why?
|
| Back Pain | 1 | 2017 | 544 | 0.100 |
Why?
|
| Outpatients | 1 | 2021 | 1595 | 0.100 |
Why?
|
| Counseling | 1 | 2021 | 1551 | 0.100 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2005 | 245 | 0.100 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2018 | 667 | 0.100 |
Why?
|
| Factor VIII | 1 | 1995 | 347 | 0.100 |
Why?
|
| Glucose Intolerance | 1 | 2016 | 580 | 0.100 |
Why?
|
| Hospitals, Public | 1 | 2013 | 203 | 0.100 |
Why?
|
| Norway | 1 | 2013 | 499 | 0.100 |
Why?
|
| Health Status | 4 | 2015 | 4080 | 0.100 |
Why?
|
| Risk Management | 1 | 2015 | 559 | 0.100 |
Why?
|
| Utilization Review | 1 | 2013 | 381 | 0.100 |
Why?
|
| Treatment Outcome | 10 | 2024 | 65188 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 1560 | 0.090 |
Why?
|
| Hemophilia A | 1 | 1995 | 357 | 0.090 |
Why?
|
| Prediabetic State | 1 | 2017 | 548 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 10383 | 0.090 |
Why?
|
| Myocardial Infarction | 4 | 2002 | 11499 | 0.090 |
Why?
|
| Prepaid Health Plans | 1 | 2010 | 9 | 0.090 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 939 | 0.090 |
Why?
|
| Hospitalists | 2 | 2007 | 297 | 0.090 |
Why?
|
| Psychometrics | 2 | 2008 | 3062 | 0.090 |
Why?
|
| Hospitals, Maternity | 1 | 2011 | 32 | 0.090 |
Why?
|
| Anxiety | 1 | 2006 | 4671 | 0.090 |
Why?
|
| Community Mental Health Centers | 1 | 2011 | 91 | 0.090 |
Why?
|
| Comorbidity | 5 | 2014 | 10563 | 0.090 |
Why?
|
| Histamine H2 Antagonists | 2 | 2005 | 168 | 0.090 |
Why?
|
| Bariatric Surgery | 1 | 2020 | 997 | 0.090 |
Why?
|
| Mass Media | 4 | 2003 | 301 | 0.090 |
Why?
|
| Decision Making, Organizational | 1 | 2010 | 136 | 0.090 |
Why?
|
| Antimanic Agents | 1 | 2014 | 523 | 0.090 |
Why?
|
| International Agencies | 1 | 1991 | 240 | 0.080 |
Why?
|
| Suicidal Ideation | 1 | 2020 | 1461 | 0.080 |
Why?
|
| Telemedicine | 2 | 2019 | 3105 | 0.080 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2014 | 790 | 0.080 |
Why?
|
| Hypnotics and Sedatives | 3 | 2015 | 1191 | 0.080 |
Why?
|
| Pharmacoepidemiology | 3 | 2015 | 351 | 0.080 |
Why?
|
| Clinical Competence | 2 | 2006 | 4863 | 0.080 |
Why?
|
| Headache | 1 | 2017 | 1259 | 0.080 |
Why?
|
| Organizations, Nonprofit | 1 | 2010 | 105 | 0.080 |
Why?
|
| Health Services Misuse | 4 | 2016 | 245 | 0.080 |
Why?
|
| Maine | 4 | 2011 | 146 | 0.080 |
Why?
|
| Hepatitis C | 1 | 2019 | 1597 | 0.080 |
Why?
|
| Patient Satisfaction | 3 | 2017 | 3475 | 0.080 |
Why?
|
| Postpartum Period | 1 | 2016 | 1205 | 0.080 |
Why?
|
| Pregnancy | 6 | 2021 | 30260 | 0.080 |
Why?
|
| Low Back Pain | 1 | 2017 | 987 | 0.080 |
Why?
|
| Pediatrics | 3 | 2010 | 3606 | 0.080 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2017 | 953 | 0.080 |
Why?
|
| Analgesia | 1 | 1993 | 461 | 0.080 |
Why?
|
| Health Behavior | 1 | 2000 | 2650 | 0.080 |
Why?
|
| Body Mass Index | 4 | 2021 | 13039 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 4 | 2018 | 1806 | 0.080 |
Why?
|
| Terminal Care | 1 | 2020 | 1774 | 0.080 |
Why?
|
| Hyperlipidemias | 2 | 2011 | 770 | 0.080 |
Why?
|
| Age Distribution | 4 | 2020 | 2858 | 0.080 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 500 | 0.080 |
Why?
|
| Indonesia | 2 | 2020 | 131 | 0.080 |
Why?
|
| Sample Size | 1 | 2011 | 845 | 0.070 |
Why?
|
| Observation | 2 | 2008 | 309 | 0.070 |
Why?
|
| Electronic Prescribing | 1 | 2009 | 115 | 0.070 |
Why?
|
| Health Facilities | 2 | 2010 | 577 | 0.070 |
Why?
|
| Databases, Factual | 6 | 2020 | 8067 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 11206 | 0.070 |
Why?
|
| Cardiovascular Diseases | 5 | 2022 | 15652 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2018 | 1534 | 0.070 |
Why?
|
| Pregnancy Outcome | 1 | 2019 | 2966 | 0.070 |
Why?
|
| Anti-Infective Agents | 2 | 2010 | 986 | 0.070 |
Why?
|
| Propensity Score | 2 | 2015 | 1968 | 0.070 |
Why?
|
| Physicians, Primary Care | 1 | 2014 | 622 | 0.070 |
Why?
|
| Aromatase Inhibitors | 1 | 2011 | 518 | 0.070 |
Why?
|
| Equipment Failure | 1 | 2010 | 578 | 0.070 |
Why?
|
| Hospitals | 4 | 2020 | 3888 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2017 | 3247 | 0.070 |
Why?
|
| Prevalence | 10 | 2021 | 15842 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2024 | 4900 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2019 | 3050 | 0.070 |
Why?
|
| Substance-Related Disorders | 1 | 2004 | 4416 | 0.070 |
Why?
|
| Health Literacy | 1 | 2013 | 464 | 0.070 |
Why?
|
| Anticoagulants | 3 | 2008 | 4862 | 0.070 |
Why?
|
| Group Practice | 1 | 2008 | 149 | 0.070 |
Why?
|
| Peru | 1 | 2010 | 887 | 0.070 |
Why?
|
| Health Resources | 1 | 2013 | 949 | 0.070 |
Why?
|
| Tamoxifen | 1 | 2011 | 963 | 0.070 |
Why?
|
| Medical Staff, Hospital | 2 | 2006 | 601 | 0.070 |
Why?
|
| Analgesics | 1 | 1993 | 1060 | 0.070 |
Why?
|
| Corneal Opacity | 2 | 1986 | 52 | 0.070 |
Why?
|
| Case-Control Studies | 5 | 2023 | 22223 | 0.070 |
Why?
|
| Pilot Projects | 4 | 2020 | 8733 | 0.070 |
Why?
|
| Reproducibility of Results | 6 | 2015 | 20124 | 0.070 |
Why?
|
| Diabetes, Gestational | 1 | 2016 | 1263 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 1993 | 2268 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 15398 | 0.070 |
Why?
|
| International Cooperation | 1 | 1992 | 1432 | 0.060 |
Why?
|
| Indiana | 3 | 2011 | 93 | 0.060 |
Why?
|
| Television | 2 | 2006 | 409 | 0.060 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2006 | 102 | 0.060 |
Why?
|
| Preventive Health Services | 1 | 2010 | 570 | 0.060 |
Why?
|
| Physician Assistants | 1 | 2008 | 190 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2007 | 508 | 0.060 |
Why?
|
| Korea | 1 | 2005 | 97 | 0.060 |
Why?
|
| International Classification of Diseases | 2 | 2008 | 935 | 0.060 |
Why?
|
| Remote Consultation | 1 | 2008 | 240 | 0.060 |
Why?
|
| Michigan | 3 | 2011 | 328 | 0.060 |
Why?
|
| Sex Distribution | 4 | 2006 | 2263 | 0.060 |
Why?
|
| Respiration | 1 | 2011 | 1653 | 0.060 |
Why?
|
| Nurse Practitioners | 1 | 2008 | 272 | 0.060 |
Why?
|
| Quality Improvement | 3 | 2017 | 3853 | 0.060 |
Why?
|
| Basal Ganglia Diseases | 1 | 2005 | 145 | 0.060 |
Why?
|
| Dextropropoxyphene | 2 | 2015 | 26 | 0.060 |
Why?
|
| Proportional Hazards Models | 5 | 2014 | 12509 | 0.060 |
Why?
|
| Breast | 1 | 2014 | 1946 | 0.060 |
Why?
|
| Drug Resistance, Microbial | 1 | 2008 | 833 | 0.060 |
Why?
|
| Self Administration | 1 | 2006 | 385 | 0.060 |
Why?
|
| Morbidity | 1 | 2010 | 1749 | 0.060 |
Why?
|
| Antiparkinson Agents | 1 | 2005 | 185 | 0.060 |
Why?
|
| Peptic Ulcer | 2 | 2003 | 214 | 0.060 |
Why?
|
| Demography | 2 | 2006 | 1641 | 0.060 |
Why?
|
| Research | 1 | 1992 | 1975 | 0.060 |
Why?
|
| Video Games | 1 | 2006 | 203 | 0.060 |
Why?
|
| Fever | 1 | 2011 | 1603 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 318 | 0.060 |
Why?
|
| Urban Health Services | 1 | 2005 | 176 | 0.060 |
Why?
|
| Control Groups | 1 | 2024 | 106 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2010 | 2587 | 0.050 |
Why?
|
| Gastric Acid | 1 | 2003 | 98 | 0.050 |
Why?
|
| Half-Life | 1 | 2004 | 644 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 1514 | 0.050 |
Why?
|
| Melanoma | 1 | 2022 | 5719 | 0.050 |
Why?
|
| Formularies as Topic | 3 | 1999 | 93 | 0.050 |
Why?
|
| Population Surveillance | 2 | 2003 | 2590 | 0.050 |
Why?
|
| Diabetic Nephropathies | 1 | 2010 | 969 | 0.050 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2009 | 1195 | 0.050 |
Why?
|
| Patient Participation | 2 | 2010 | 1455 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2011 | 6499 | 0.050 |
Why?
|
| Drug Administration Schedule | 3 | 2010 | 4850 | 0.050 |
Why?
|
| Atherosclerosis | 1 | 2018 | 3424 | 0.050 |
Why?
|
| Boston | 4 | 2004 | 9338 | 0.050 |
Why?
|
| Common Cold | 1 | 2003 | 63 | 0.050 |
Why?
|
| Fluid Therapy | 2 | 1996 | 584 | 0.050 |
Why?
|
| Indazoles | 1 | 2024 | 303 | 0.050 |
Why?
|
| Albuterol | 1 | 2023 | 211 | 0.050 |
Why?
|
| Probability | 2 | 2008 | 2475 | 0.050 |
Why?
|
| Cephalothin | 1 | 2001 | 27 | 0.050 |
Why?
|
| Penicillin G | 1 | 2001 | 40 | 0.050 |
Why?
|
| Insurance, Medigap | 1 | 2001 | 20 | 0.050 |
Why?
|
| Disease Management | 3 | 2012 | 2535 | 0.050 |
Why?
|
| Reminder Systems | 2 | 2008 | 388 | 0.050 |
Why?
|
| Health Plan Implementation | 2 | 2020 | 338 | 0.050 |
Why?
|
| User-Computer Interface | 1 | 2008 | 1405 | 0.050 |
Why?
|
| Ampicillin | 1 | 2001 | 138 | 0.050 |
Why?
|
| Phthalazines | 1 | 2024 | 397 | 0.050 |
Why?
|
| Time | 1 | 2003 | 550 | 0.050 |
Why?
|
| Asia | 2 | 2013 | 628 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2007 | 906 | 0.050 |
Why?
|
| Hyperglycemia | 1 | 2010 | 1393 | 0.050 |
Why?
|
| Infant Care | 1 | 2002 | 181 | 0.050 |
Why?
|
| Mental Health Services | 2 | 2008 | 1723 | 0.050 |
Why?
|
| Community Health Centers | 1 | 2005 | 469 | 0.050 |
Why?
|
| Child Behavior | 1 | 2006 | 865 | 0.040 |
Why?
|
| Kazakhstan | 1 | 2020 | 19 | 0.040 |
Why?
|
| Hawaii | 1 | 2020 | 101 | 0.040 |
Why?
|
| Gentamicins | 1 | 2001 | 244 | 0.040 |
Why?
|
| Cataract | 2 | 1986 | 837 | 0.040 |
Why?
|
| Phototherapy | 1 | 2004 | 370 | 0.040 |
Why?
|
| Diabetic Retinopathy | 1 | 2010 | 1299 | 0.040 |
Why?
|
| Cephalosporins | 1 | 2001 | 200 | 0.040 |
Why?
|
| Medicare Part B | 1 | 2001 | 115 | 0.040 |
Why?
|
| Etretinate | 1 | 2000 | 5 | 0.040 |
Why?
|
| Postal Service | 1 | 2020 | 96 | 0.040 |
Why?
|
| Total Quality Management | 1 | 2001 | 264 | 0.040 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2003 | 352 | 0.040 |
Why?
|
| Body Weight | 2 | 2008 | 4622 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 36532 | 0.040 |
Why?
|
| Keratolytic Agents | 1 | 2000 | 34 | 0.040 |
Why?
|
| Medical Records | 2 | 2010 | 1409 | 0.040 |
Why?
|
| Eating | 1 | 2006 | 1540 | 0.040 |
Why?
|
| Proton Pump Inhibitors | 1 | 2005 | 553 | 0.040 |
Why?
|
| Depression | 3 | 2015 | 8237 | 0.040 |
Why?
|
| Journalism, Medical | 1 | 2000 | 73 | 0.040 |
Why?
|
| Glaucoma | 1 | 1989 | 1194 | 0.040 |
Why?
|
| Weight Gain | 1 | 2010 | 2355 | 0.040 |
Why?
|
| Community-Acquired Infections | 1 | 2003 | 470 | 0.040 |
Why?
|
| Cameroon | 2 | 1996 | 79 | 0.040 |
Why?
|
| Health Planning | 1 | 2001 | 233 | 0.040 |
Why?
|
| Dihydropyridines | 1 | 1999 | 66 | 0.040 |
Why?
|
| Ethanol | 1 | 2005 | 1323 | 0.040 |
Why?
|
| Minnesota | 1 | 1999 | 336 | 0.040 |
Why?
|
| Activities of Daily Living | 2 | 2015 | 2415 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2005 | 856 | 0.040 |
Why?
|
| Economics, Pharmaceutical | 2 | 2014 | 88 | 0.040 |
Why?
|
| Insurance Carriers | 1 | 2020 | 159 | 0.040 |
Why?
|
| Milk, Human | 1 | 2003 | 490 | 0.040 |
Why?
|
| Qualitative Research | 2 | 2020 | 3139 | 0.040 |
Why?
|
| Gastroesophageal Reflux | 2 | 2003 | 833 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2000 | 525 | 0.040 |
Why?
|
| Computer Communication Networks | 1 | 2000 | 292 | 0.040 |
Why?
|
| United States Food and Drug Administration | 3 | 2015 | 1672 | 0.040 |
Why?
|
| Government Programs | 1 | 2020 | 278 | 0.040 |
Why?
|
| Reference Values | 2 | 2019 | 4908 | 0.040 |
Why?
|
| Maternal Health Services | 1 | 2003 | 472 | 0.040 |
Why?
|
| Atrial Fibrillation | 2 | 2006 | 5189 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2019 | 15747 | 0.030 |
Why?
|
| Prognosis | 2 | 2011 | 29922 | 0.030 |
Why?
|
| Survival Rate | 1 | 2011 | 12795 | 0.030 |
Why?
|
| Family | 2 | 2021 | 3209 | 0.030 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 1998 | 198 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 4 | 2010 | 5526 | 0.030 |
Why?
|
| Aspirin | 3 | 2000 | 3134 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 3537 | 0.030 |
Why?
|
| Professional Practice | 2 | 2009 | 313 | 0.030 |
Why?
|
| Diarrhea, Infantile | 1 | 1996 | 100 | 0.030 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2001 | 644 | 0.030 |
Why?
|
| Economic Competition | 1 | 2018 | 223 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2001 | 1731 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2007 | 2660 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2021 | 1816 | 0.030 |
Why?
|
| Heart Failure | 2 | 2017 | 11840 | 0.030 |
Why?
|
| Peer Review, Research | 1 | 2019 | 341 | 0.030 |
Why?
|
| Indoles | 1 | 2024 | 1839 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 10729 | 0.030 |
Why?
|
| Attitude to Health | 4 | 2007 | 2020 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 1999 | 686 | 0.030 |
Why?
|
| Vitamin A Deficiency | 1 | 1996 | 88 | 0.030 |
Why?
|
| Emergency Treatment | 1 | 1999 | 494 | 0.030 |
Why?
|
| Losartan | 1 | 2017 | 263 | 0.030 |
Why?
|
| Housing | 1 | 2000 | 683 | 0.030 |
Why?
|
| Piperidines | 1 | 2024 | 1664 | 0.030 |
Why?
|
| Trachoma | 1 | 1995 | 19 | 0.030 |
Why?
|
| Patient Simulation | 1 | 1997 | 301 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 2001 | 851 | 0.030 |
Why?
|
| Psychiatry | 1 | 2007 | 1714 | 0.030 |
Why?
|
| Self Report | 2 | 2019 | 3770 | 0.030 |
Why?
|
| Risk Assessment | 4 | 2019 | 24282 | 0.030 |
Why?
|
| Portugal | 1 | 2014 | 90 | 0.030 |
Why?
|
| Child Day Care Centers | 2 | 2005 | 122 | 0.030 |
Why?
|
| Rural Population | 3 | 1996 | 2317 | 0.030 |
Why?
|
| Vision, Low | 1 | 1996 | 162 | 0.030 |
Why?
|
| Mood Disorders | 1 | 2020 | 1128 | 0.030 |
Why?
|
| Databases as Topic | 2 | 2009 | 471 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1999 | 1237 | 0.030 |
Why?
|
| Pacific Islands | 1 | 2013 | 52 | 0.030 |
Why?
|
| Piperazines | 1 | 2024 | 2549 | 0.030 |
Why?
|
| Incidence | 4 | 2008 | 21480 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2004 | 1660 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2002 | 1846 | 0.030 |
Why?
|
| Decision Making | 2 | 2007 | 3965 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2016 | 1180 | 0.030 |
Why?
|
| Finland | 1 | 2014 | 608 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 2002 | 2059 | 0.030 |
Why?
|
| Vitamin A | 1 | 1996 | 610 | 0.030 |
Why?
|
| Renin-Angiotensin System | 1 | 2017 | 737 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2001 | 1431 | 0.030 |
Why?
|
| Homes for the Aged | 2 | 1992 | 273 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1996 | 1526 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2001 | 1543 | 0.020 |
Why?
|
| Focus Groups | 1 | 2018 | 1459 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 6309 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2016 | 697 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2000 | 1303 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2018 | 1187 | 0.020 |
Why?
|
| Equipment Design | 1 | 2019 | 3481 | 0.020 |
Why?
|
| Survival Analysis | 3 | 2016 | 10070 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2014 | 5302 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 2015 | 590 | 0.020 |
Why?
|
| HIV-1 | 1 | 2008 | 6944 | 0.020 |
Why?
|
| Pharmacopoeias as Topic | 1 | 2010 | 16 | 0.020 |
Why?
|
| Genes, BRCA2 | 1 | 2014 | 588 | 0.020 |
Why?
|
| State Government | 1 | 2013 | 388 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2017 | 1149 | 0.020 |
Why?
|
| Consumer Health Information | 1 | 2013 | 215 | 0.020 |
Why?
|
| Behavior Therapy | 1 | 1996 | 884 | 0.020 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2011 | 212 | 0.020 |
Why?
|
| Genes, BRCA1 | 1 | 2014 | 750 | 0.020 |
Why?
|
| West Indies | 1 | 1989 | 32 | 0.020 |
Why?
|
| Fibrinolytic Agents | 1 | 1999 | 2080 | 0.020 |
Why?
|
| Mexico | 1 | 2012 | 777 | 0.020 |
Why?
|
| Urban Health | 2 | 1996 | 530 | 0.020 |
Why?
|
| Motivation | 2 | 1996 | 2018 | 0.020 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2010 | 134 | 0.020 |
Why?
|
| Uremia | 1 | 1990 | 202 | 0.020 |
Why?
|
| Reoperation | 1 | 2019 | 4294 | 0.020 |
Why?
|
| Administrative Personnel | 1 | 2010 | 186 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2013 | 629 | 0.020 |
Why?
|
| Environment | 1 | 1995 | 1114 | 0.020 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2010 | 142 | 0.020 |
Why?
|
| Drug Substitution | 1 | 2011 | 292 | 0.020 |
Why?
|
| Rural Health | 2 | 1996 | 301 | 0.020 |
Why?
|
| Databases, Bibliographic | 1 | 2008 | 128 | 0.020 |
Why?
|
| Energy Intake | 1 | 1996 | 2141 | 0.020 |
Why?
|
| Africa South of the Sahara | 1 | 2010 | 751 | 0.020 |
Why?
|
| Pharmacists | 1 | 2010 | 260 | 0.020 |
Why?
|
| Buprenorphine | 1 | 2015 | 665 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2008 | 150 | 0.020 |
Why?
|
| Enema | 1 | 2008 | 140 | 0.020 |
Why?
|
| Europe | 1 | 2014 | 3423 | 0.020 |
Why?
|
| Comprehension | 1 | 2013 | 638 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2001 | 5912 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 2011 | 647 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 714 | 0.020 |
Why?
|
| Hydrocodone | 1 | 2006 | 48 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 1993 | 1297 | 0.020 |
Why?
|
| Palliative Care | 1 | 2022 | 3645 | 0.020 |
Why?
|
| Child Welfare | 1 | 2010 | 521 | 0.020 |
Why?
|
| Exercise | 1 | 2023 | 5937 | 0.020 |
Why?
|
| Electrocardiography | 1 | 1999 | 6404 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 1992 | 1166 | 0.020 |
Why?
|
| Diffusion of Innovation | 1 | 1990 | 721 | 0.020 |
Why?
|
| Saudi Arabia | 1 | 1986 | 211 | 0.020 |
Why?
|
| Automation | 1 | 2008 | 585 | 0.020 |
Why?
|
| Epidemiologic Methods | 2 | 2006 | 1326 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 4893 | 0.020 |
Why?
|
| Chlorpromazine | 1 | 2005 | 111 | 0.020 |
Why?
|
| Vaginal Smears | 1 | 2008 | 513 | 0.010 |
Why?
|
| Mortality | 1 | 2016 | 2904 | 0.010 |
Why?
|
| Alcohols | 1 | 2005 | 94 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 3432 | 0.010 |
Why?
|
| Dopamine Antagonists | 1 | 2005 | 278 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2008 | 967 | 0.010 |
Why?
|
| Obesity | 1 | 2006 | 13076 | 0.010 |
Why?
|
| Methadone | 1 | 2006 | 319 | 0.010 |
Why?
|
| Evidence-Based Medicine | 2 | 2008 | 3685 | 0.010 |
Why?
|
| Hospitals, Teaching | 2 | 2002 | 1158 | 0.010 |
Why?
|
| Restaurants | 1 | 2006 | 235 | 0.010 |
Why?
|
| Gels | 1 | 2005 | 419 | 0.010 |
Why?
|
| Haloperidol | 1 | 2005 | 391 | 0.010 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2006 | 252 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2015 | 2039 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 9373 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2008 | 1749 | 0.010 |
Why?
|
| Physician-Patient Relations | 2 | 2008 | 3278 | 0.010 |
Why?
|
| Specialization | 1 | 2008 | 777 | 0.010 |
Why?
|
| Life Style | 1 | 1995 | 3926 | 0.010 |
Why?
|
| Recurrence | 1 | 2015 | 8501 | 0.010 |
Why?
|
| Speech | 1 | 2008 | 555 | 0.010 |
Why?
|
| Infant Food | 1 | 2003 | 139 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 1370 | 0.010 |
Why?
|
| Risperidone | 1 | 2005 | 383 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2015 | 2176 | 0.010 |
Why?
|
| Morphine | 1 | 2006 | 660 | 0.010 |
Why?
|
| Mental Recall | 1 | 2008 | 1218 | 0.010 |
Why?
|
| Eye Diseases | 2 | 1990 | 659 | 0.010 |
Why?
|
| Communication | 1 | 1996 | 3916 | 0.010 |
Why?
|
| Interprofessional Relations | 1 | 2008 | 999 | 0.010 |
Why?
|
| Internal Medicine | 1 | 2009 | 1064 | 0.010 |
Why?
|
| Endometritis | 1 | 2001 | 49 | 0.010 |
Why?
|
| Hospitals, Voluntary | 1 | 2001 | 39 | 0.010 |
Why?
|
| Perception | 1 | 2008 | 1205 | 0.010 |
Why?
|
| Fruit | 1 | 2006 | 1166 | 0.010 |
Why?
|
| Vegetables | 1 | 2006 | 1199 | 0.010 |
Why?
|
| Opioid-Related Disorders | 1 | 2015 | 2178 | 0.010 |
Why?
|
| Colombia | 1 | 2001 | 287 | 0.010 |
Why?
|
| Body Height | 1 | 2006 | 1562 | 0.010 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2009 | 1175 | 0.010 |
Why?
|
| Medicine | 1 | 2008 | 942 | 0.010 |
Why?
|
| Community Networks | 1 | 2001 | 203 | 0.010 |
Why?
|
| Geriatric Assessment | 1 | 2007 | 1429 | 0.010 |
Why?
|
| Thromboembolism | 1 | 2006 | 1003 | 0.010 |
Why?
|
| Nicardipine | 1 | 1999 | 59 | 0.010 |
Why?
|
| Alendronate | 1 | 2000 | 174 | 0.010 |
Why?
|
| Vision Disorders | 1 | 1986 | 1087 | 0.010 |
Why?
|
| Nifedipine | 1 | 1999 | 220 | 0.010 |
Why?
|
| Diltiazem | 1 | 1999 | 132 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 18071 | 0.010 |
Why?
|
| Verapamil | 1 | 1999 | 242 | 0.010 |
Why?
|
| Pravastatin | 1 | 2000 | 391 | 0.010 |
Why?
|
| Hospital Mortality | 2 | 2002 | 5343 | 0.010 |
Why?
|
| Diet | 1 | 1996 | 8086 | 0.010 |
Why?
|
| Ethics | 1 | 1997 | 93 | 0.010 |
Why?
|
| Emergency Medical Services | 1 | 2009 | 1938 | 0.010 |
Why?
|
| Pharmacogenetics | 1 | 2001 | 682 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2006 | 2393 | 0.010 |
Why?
|
| Selection Bias | 1 | 1998 | 361 | 0.010 |
Why?
|
| Visual Acuity | 1 | 1986 | 2708 | 0.010 |
Why?
|
| Animals | 2 | 2018 | 168764 | 0.010 |
Why?
|
| Drug Information Services | 1 | 1996 | 51 | 0.010 |
Why?
|
| Home Care Services | 1 | 2002 | 660 | 0.010 |
Why?
|
| Persuasive Communication | 1 | 1996 | 58 | 0.010 |
Why?
|
| Mutation | 1 | 2020 | 30198 | 0.010 |
Why?
|
| Conflict of Interest | 1 | 2000 | 556 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2011 | 8532 | 0.010 |
Why?
|
| Family Planning Services | 1 | 1997 | 278 | 0.010 |
Why?
|
| Patient Advocacy | 1 | 1997 | 361 | 0.010 |
Why?
|
| Disclosure | 1 | 2000 | 756 | 0.010 |
Why?
|
| Stroke | 2 | 2006 | 9747 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2006 | 3461 | 0.010 |
Why?
|
| Perioperative Care | 1 | 2001 | 1055 | 0.010 |
Why?
|
| Inservice Training | 1 | 1996 | 375 | 0.010 |
Why?
|
| Aging | 1 | 1992 | 8731 | 0.010 |
Why?
|
| Quality of Life | 1 | 1995 | 13462 | 0.010 |
Why?
|
| Anticholesteremic Agents | 1 | 2000 | 970 | 0.010 |
Why?
|
| Cost Savings | 1 | 1998 | 904 | 0.010 |
Why?
|
| Consumer Organizations | 1 | 1992 | 10 | 0.010 |
Why?
|
| Education, Nursing, Continuing | 1 | 1992 | 68 | 0.010 |
Why?
|
| Prothrombin Time | 1 | 1992 | 116 | 0.010 |
Why?
|
| Geriatric Psychiatry | 1 | 1992 | 70 | 0.010 |
Why?
|
| Education, Continuing | 1 | 1992 | 115 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 3251 | 0.010 |
Why?
|
| Mental Processes | 1 | 1992 | 243 | 0.010 |
Why?
|
| Hospitals, Community | 1 | 1993 | 363 | 0.010 |
Why?
|
| Osteoporosis | 1 | 2000 | 1582 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1990 | 189 | 0.010 |
Why?
|
| Institutionalization | 1 | 1990 | 108 | 0.010 |
Why?
|
| Politics | 1 | 1997 | 822 | 0.010 |
Why?
|
| Patient Selection | 1 | 2002 | 4255 | 0.010 |
Why?
|
| Electrolytes | 1 | 1990 | 280 | 0.010 |
Why?
|
| Parents | 1 | 2002 | 3592 | 0.000 |
Why?
|
| Urban Population | 1 | 1996 | 2040 | 0.000 |
Why?
|
| Drug Interactions | 1 | 1992 | 1417 | 0.000 |
Why?
|
| Algorithms | 1 | 2008 | 14071 | 0.000 |
Why?
|
| Risk | 1 | 1999 | 9591 | 0.000 |
Why?
|
| Biomedical Research | 1 | 2000 | 3458 | 0.000 |
Why?
|
| Forecasting | 1 | 1993 | 2936 | 0.000 |
Why?
|
| Prospective Studies | 2 | 2003 | 54802 | 0.000 |
Why?
|
| Surgical Procedures, Operative | 1 | 1993 | 1941 | 0.000 |
Why?
|
| Analysis of Variance | 1 | 1990 | 6203 | 0.000 |
Why?
|